Interest in novel therapeutics continues, evidenced by the announcement by oncology biotech Turning Point (TPTX) that it increased the number of shares by 20% to 8.8 million, giving it a market cap of $547 million and $237 million in cash.
Turning Point is developing second generation tyrosine kinase inhibitors (TKI), with its lead candidate repotrectinib in a 75-patient Phase 1 trial for non-small cell lung cancer (NSCLC).
Here are three things you should know about Turning Point.
To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.
